BioNTech founders have outsized ambitions; researchers report faster brain imaging technique

After the Covid-19 vaccine, BioNTech founders Ugur Sahin and Ozlem Tureci want to create a new kind of drug company. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: Flush with cash from Covid-19 vaccine, BioNTech founders have outsized ambitions By Matthew Herper Matthew Herper/STAT “We will use the chance – this historic chance – to build a global pharmaceutical company,” said BioNTech CEO Ugur Sahin. Read More Faster brain imaging technique seems to overcome limitations of current MRI scans By Brittany Trang Courtesy Jang-Yeon The new technique promises to overcome limitations of current imaging methods such as fMRI, a mainstay of neuroscience for three decades. Read More STAT+: AstraZeneca is fined by South Korea for an anticompetitive deal over a cancer drug By Ed Silverman Adobe This is the latest instance in which a global pharmaceutical company has been cited for anticompetitive behavior. Read More Sponsor content by Biogen Biogen Community Lab opens door to STEM for underrepresented students Juan Rafael Lenger-Caballero is finding ways to help those living with mobility challenges, like his father. Learn about him and the impact of 20 years of the Biogen Community Lab, a free science education program that aims to inspire the next generation of STEM leaders. Hear how Juan Rafael grew inspired by the Community Lab. STAT+: Alphabet's AI predicted the structure of 200 million proteins. Can it really speed up drug discovery? By Brittany Trang Courtesy DeepMind AlphaFold’s ingenious application of AI will result in steady advances, but this does not unlock hyperspeed in the quest for cures. Read More STAT+: Relmada antidepressant drug fails first of several late-stage clinical trials By Adam Feuerstein APStock The drug, a pill called REL-1017, did not show a statistically significant, anti-depressive benefit compared with a placebo. Read More Opinion: The global diabetes crisis few are talking about By Aaron J. Kowalski Rodrigo Abd/AP The Type 1 Diabetes Index quantifies the death toll of this disease in countries around the globe, putting it on par with HIV/AIDS. Read More Opinion: Why the U.S. needs a public benefit biopharma industry By Barbara Handelin and Sandra Heibel Adobe Biopharma is failing Americans, both medically and economically. We need a public benefit biopharma industry. Read More Thursday, October 13, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser